key: cord-0853303-qxgluckl
authors: Kubin, Christine J; McConville, Thomas H; Dietz, Donald; Zucker, Jason; May, Michael; Nelson, Brian; Istorico, Elizabeth; Bartram, Logan; Small-Saunders, Jennifer; Sobieszczyk, Magdalena E; Gomez-Simmonds, Angela; Uhlemann, Anne-Catrin
title: Characterization of Bacterial and Fungal Infections in Hospitalized Patients with COVID-19 and Factors Associated with Healthcare-associated Infections
date: 2021-05-05
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab201
sha: 5e16d79cd67cefa93da92b4095d78f58edc3f40f
doc_id: 853303
cord_uid: qxgluckl

BACKGROUND: Patients hospitalized with COVID-19 are at increased risk of healthcare-associated infections especially with prolonged hospital stays. We sought to identify incidence, antimicrobial susceptibilities, and outcomes associated with bacterial/fungal secondary infections in a large cohort of patients with COVID-19. METHODS: We evaluated adult patients diagnosed with COVID-19 between March 2 to May 31, 2020 and hospitalized >24 hours. Data extracted from medical records included diagnoses, vital signs, laboratory results, microbiological data, and antibiotic use. Microbiologically-confirmed bacterial and fungal pathogens from clinical cultures were evaluated to characterize community- and healthcare-associated infections, including describing temporal changes in predominant organisms on presentation and throughout hospitalization. Univariable and multivariable logistic regression analyses were performed to investigate risk factors for healthcare-associated infections. RESULTS: A total of 3,028 patients were included and accounted for 899 positive clinical cultures. Overall, 516 (17%) with positive cultures met criteria for infection. Community-associated co-infections were identified in 183 (6%) patients, whereas healthcare-associated infections occurred in 350 (12%) patients. 57% of healthcare-associated infections were caused by Gram-negative bacteria and 19% by fungi. Antibiotic resistance increased with longer hospital stays, with incremental increases in the proportion of vancomycin-resistance among enterococci and ceftriaxone- and carbapenem-resistance among Enterobacterales. ICU stay, invasive mechanical ventilation, and steroids were associated with healthcare-associated infections. CONCLUSIONS: Healthcare-associated infections occur in a small proportion of patients hospitalized with COVID-19 and are most often caused by Gram-negative and fungal pathogens. Antibiotic resistance is more prevalent with prolonged hospital stays. Antimicrobial stewardship is imperative in this population to minimize unnecessary broad-spectrum antibiotics.

A c c e p t e d M a n u s c r i p t 5 Introduction:

The novel coronavirus SARS-CoV-2 has been accompanied by the widespread use of empiric broadspectrum antimicrobial agents attributed to liberalization of antibiotic stewardship approaches in a time of clinical uncertainty and significant strain on healthcare systems. 1,2 Development of bacterial or fungal superinfections are well-established risk factors for poor outcomes in patients with influenza pneumonia 3 , such as intensive care unit (ICU) admission and mortality, and have also been reported in patients with respiratory syndromes due to other coronaviruses, including SARS and MERS. [4] [5] [6] [7] However, the incidence and identity of bacteria and fungi causing secondary infections in COVID-19 patients remains unclear.

In early reports from China, secondary infections were identified in up to 50% of patients who died from COVID-19, compared to only 15% of patients that did not. 8 However, the proportion of patients receiving empiric antibiotics has been shown to greatly exceed those with culture-proven infections. In a recent retrospective review of published studies (n=806 patients), bacterial and fungal co-infections were reported in only 8% of patients, while more than 70% of patients received empiric antibacterial therapy. 2 Similarly, in a large meta-analysis of nearly 4,000 hospitalized patients with COVID-19, predominantly from China, only 7% were found to have bacterial coinfections, which increased to 14% in critically-ill patients. 9 Little is known about the characteristics of secondary infections in patients with Many published studies fail to adequately describe the timing of identified infections, making it difficult to distinguish between community-associated co-infection or healthcare-associated infection. In addition, few prior studies describe causative organisms and antibiotic susceptibilities, and follow-up time is often limited. The impact of immunomodulatory agents, such as corticosteroids and IL-6 receptor blockers, on the incidence of secondary infections is unknown, despite the widespread use of these agents to manage inflammatory complications of 12 A c c e p t e d M a n u s c r i p t 6 Here we aimed to systematically characterize community-and healthcare-associated bacterial and fungal infections in hospitalized patients with COVID-19, including temporal changes in predominant organisms on presentation and throughout the hospital course. We further investigated clinical risk factors for healthcare-associated infections.

This was a retrospective cohort study conducted at a quaternary medical center in New York City, which includes a large academic medical center and a small community hospital, both located in northern Manhattan. Patients were included if they were 18 years or older, presented to the emergency department between March 2, 2020 and May 31, 2020, tested positive for SARS-CoV-2 by RT-PCR from a nasopharyngeal swab sample, and were hospitalized >24 hours. We extracted clinical and demographic information from the patients' electronic medical records (EMR). This included admission diagnoses, vital signs, laboratory results, microbiological data, antibiotic use data, and discharge dates. International classification of disease codes (ICD-9 and 10) were used to identify comorbidities for calculating the Charlson Comorbidity Index Score (CCIS).

During the study period, patients with COVID-19 were managed according to internal guidelines, which underwent several updates during the study period to reflect the rapid evolution of available evidence and experience. Initially, this included the use of hydroxychloroquine with or without azithromycin in patients with severe disease. Additionally, patients with evidence of acute respiratory distress syndrome or other inflammatory complications were considered for receipt of low-dose methylprednisolone (0.5 mg/kg/dose q12 hours) and/or the IL-6 receptor blocker tocilizumab. Patients meeting respective criteria were approached for enrollment in randomized A c c e p t e d M a n u s c r i p t 7 clinical trials studying sarilumab (an alternative IL-6 receptor blocker), remdesivir, or convalescent plasma.

The Columbia University institutional review board approved this study and waived the need for informed consent.

Culture and susceptibility results from all body sources were extracted from patients' EMR. Only bacterial and fungal organisms were considered. For each unique organism, only the first isolate collected at a given body site per patient was included in the analysis. Surveillance cultures from nares and rectal swabs and autopsy cultures were excluded. Community-associated co-infections were defined as those in which the positive culture was isolated in the first 72 hours of hospitalization or within five days prior to admission from an outpatient or emergency department visit. Healthcare-associated infections, in which the positive culture was obtained after hospital day 3, were further subdivided into infections detected on days 4-14, 15-28, or after hospital day 28.

Bacteremia was defined by a positive blood culture for any organism other than coagulasenegative Staphylococci. Criteria for bacteremia due to coagulase-negative Staphylococci included positive blood cultures for at least two consecutive days and receipt of an anti-staphylococcal antibiotic; if these criteria were not met, the blood culture was regarded as contaminated. All respiratory isolates except Candida and Enterococcus sp. were considered to indicate the presence of pneumonia as protocols at our institution recommend culturing only in the setting of worsening symptoms or fever. Ventilator-associated pneumonia was defined by organism isolation from a respiratory source more than two calendar days after intubation. Organisms isolated from urinary A c c e p t e d M a n u s c r i p t 8 cultures were challenging to evaluate for infection, given the difficulty of assessing symptoms in this critically ill patient population. All urinary isolates with an associated urinalysis with >10 white blood cells per high power field were considered to constitute a urinary tract infection. Table 1 .

A total of 221 cultures from 183 patients (6%) were identified as co-infections within 72 hours of hospital admission. The majority were isolated from the urine (112/221, 51%), followed by blood (69/221, 31%) and respiratory tract (26/221, 12%). Fourteen isolates (6%) were identified from other sources, including three each from peritoneal fluid and wounds. The most common organisms identified were E. coli (68/221, 31%), S. aureus (25/221, 11%), Proteus mirabilis (18/221, 8%), and K.

pneumoniae (17/221, 8%) . E. coli accounted for 58/112 (52%) isolates from the urinary tract, while S. aureus was most frequently isolated from the respiratory tract (13/26; 50%). S. aureus and E. coli each accounted for 9/69 (13%) of community-associated bacteremias.

Healthcare-associated infections were identified in 350 (12%) patients, with the median onset of infection on hospital day 16 (IQR 9,25). Among the 678 isolates identified as healthcare-associated, 385 (57%) were Gram-negative bacteria, 167 (25%) Gram-positive bacteria, and 126 (19%) fungi. The frequency of organisms and time of isolation are described in Table 2 .

A c c e p t e d M a n u s c r i p t 10 A total of 94 patients with COVID-19 accounted for 133 organisms isolated from blood cultures. The median time from hospital admission to first healthcare-associated bacteremia was 23 days (IQR 15,37 days). Gram-positive organisms accounted for 42% of bacteremias, followed by Gram-negative organisms (35%), and fungi (22%). All but one fungal pathogen isolated from blood cultures were Candida species. Overall, Enterobacterales was the most common organism group isolated from blood cultures (26%). However, bacteremias caused by Staphylococci and Streptococci were more frequent earlier in the hospital stay (see Figure 1 ). They accounted for 15/29 (52%) bacteremias occurring within the first 14 days, compared to 12/47 (26%) occurring during hospitals days 15 to 28 and 9/57 (16%) beyond hospital day 28. Enterobacterales were the most common cause of bacteremias occurring beyond hospital day 28 (19/57, 33%).

There were 207 patients with 298 healthcare-associated respiratory isolates identified during the study period. Respiratory isolates were classified as hospital-acquired in 17% and ventilator-associated in 83%. Enterobacterales, Staphylococci, and Pseudomonas species were the most common organism groups and accounted for 89% of respiratory pathogens (see Table 2 ).

Staphylococci were more commonly (35%) isolated early (within the first 14 days). Beyond day 14 of hospitalization, Enterobacterales and Pseudomonas species predominated, comprising 75% of respiratory isolates.

Urine isolates accounted for 216 healthcare-associated isolates, and consisted predominantly of Enterobacterales, and Enterococci (81%). An additional 31 isolates were identified from sites other than the blood, respiratory tract, or urine, including 17 (55%) from unspecified wound cultures. The majority of these isolates were collected beyond hospital day 28 (65%).

A c c e p t e d M a n u s c r i p t 11

Among the entire cohort of 3,028 patients, 2,015 (67%) had exposure to at least one dose of an antibiotic. This includes 2,512 patients without a microbiologically confirmed bacterial or fungal infection, of whom 1,518 (60%) had any antibiotic exposure. Among those with healthcareassociated infections, 340 (97%) had exposure to antibiotics. The most commonly used antibiotics prior to infection in patients who went on to develop a healthcare-associated infection included broad-spectrum penicillins (65%), cephalosporins (59%), anti-staphylococcal agents with activity against MRSA (56%), and tetracyclines (26%). Exposure to carbapenems (15%) and quinolones (5%) was less common.

Drug susceptibilities differed by source of infection and duration of hospitalization, with the proportion of VRE, Ceph-R Enterobacterales, and CRE infections increasing with duration of hospitalization (see Figure 2 ). MRSA was identified in 38/116 (33%) of Staphylococcus aureus isolates, all but nine of which were isolated from the respiratory tract (76%). VRE accounted for 18/50 (36%) of Enterococci. Seven VRE bacteremias and 9 VRE urine isolates were identified including three causing community-acquired infections. Cephalosporin-resistant Enterobacterales was the most common organism group with multidrug-resistance, identified in 159 isolates. Ceph-R Enterobacterales accounted for a larger proportion of infections occurring on hospitals days 15 to 28 (49%) and after hospital day 28 (50%), compared to community-acquired infections (27%) and

infections on hospitals days 4 to 14 (41%). Moreover, while the urine was the most common source of Ceph-R Enterobacterales community-associated infections (23/31, 74%), the respiratory tract was the most common source of infection thereafter (71/128, 55%). We identified 27 CRE isolates, most of which occurred after day 28 of hospitalization (78%) and were isolated from the respiratory tract (52%). 13 Four bacteremias caused by CRE were identified and all four occurred after day 28 of hospitalization. Carbapenem-resistant Pseudomonas and Acinetobacter species were infrequent, and also consisted largely of respiratory tract infections occurring beyond day 14 of hospitalization.

A c c e p t e d M a n u s c r i p t

Patients with a healthcare-associated infection were significantly older and more likely to be male.

These patients were also more likely to require ICU care, require invasive mechanical ventilation, receive COVID-specific therapies, and have more exposure to broad-spectrum antibiotics prior to infection (see Table 3 was performed focusing only on healthcare-associated bacteremia and respiratory infections as the dependent variable. The same variables (ICU care, invasive mechanical ventilation, and steroids) plus male sex and not receiving an anti-MRSA antibiotic were independently associated with healthcareassociated infection (see supplemental Table 1 ).

Among this large cohort of COVID-19 patients, we detected notable temporal changes in the frequency of infection types and antimicrobial resistance patterns from the time of hospitalization to over 28 days after admission. Only 6% presented with a community-associated bacterial or fungal co-infection, consisting largely of Gram-negative urinary tract infections. Microbiologically confirmed healthcare-associated infections occurred in 12% of the patients over the course of the hospital stay.

Gram-negative organisms accounted for 58% of all infections and increased in frequency with longer hospital stay, while staphylococci accounted for the majority of Gram-positive organisms (57%). We also detected a relatively large proportion of fungal infections (15%), consisting primarily of hospitalassociated Candida spp. Importantly, the proportion of resistant isolates increased with duration of A c c e p t e d M a n u s c r i p t 13 hospital stay, particularly with incremental increases in the proportion of vancomycin-resistance among enterococci and ceftriaxone-resistance and carbapenem-resistance among Enterobacterales.

Previous studies have reported variable rates of both community-and hospital-associated secondary infections in adult patients of 0-17% and 0-43%, respectively. 14-34 Differences in the patient population, culture sources, and pathogens of interest are likely responsible for the wide variations reported. The two largest studies assessing for co-infection at the time of hospital admission reported incidence between 1-3% but included detection of viral respiratory pathogens and Mycoplasma. 28,32 Among studies reporting the proportion of patients with hospital-associated infections, disease severity and follow-up time also varied. For example, two studies of ICU patients reported notably different secondary infections rates, with one reporting that 37% of patients developed secondary bacteremia and the other detecting hospital-associated bacterial or fungal infection in 14% of patients. 17, 19 Similarly, a review of patients over the age of 60 in which 54% were still hospitalized at day 28 reported 43% of patients developing secondary infection; however, the characteristics of these infections were not described. 27 While a relatively large proportion of patients in this study developed secondary infections (17%), we and others found that this was greatly exceeded by the proportion of patients receiving antibiotics, which reached 90% in some studies. 33, 34 In previous studies, antimicrobials were initiated upon initial presentation, despite the relatively low rates of bacterial co-infections reported. Our study documented antibiotic exposure at any point during the hospitalization in 60% of patients. High rates of antimicrobial use in conjunction with other risk factors, such as prolonged hospital and ICU stays, invasive devices, and the need for patient cohorting, may have contributed to the increasing incidence of multidrug-resistant infections over the course of hospitalizations. MRSA was infrequent among S. aureus isolates within the first 14 days of hospitalization. Similarly, VRE was not common in the initial 14 days with both MRSA and VRE increasing to >40% beyond 14 days. This suggests that broad-spectrum Gram-positive agents may not be necessary early on in the hospital A c c e p t e d M a n u s c r i p t 14 course and therefore potential targets for antimicrobial stewardship programs. Among Gramnegative organisms, Ceph-R Enterobacterales were common urinary isolates early and likely reflect extended-spectrum beta-lactamase producing organisms present in the community. Of concern is the isolation of CRE among Enterobacterales at 4.2% during hospital days 15 to 28 and 19% beyond day 28. Population structure and mechanisms of resistance among carbapenemase-producing Enterobacterales in COVID-19 patients was previously reported from our institution. 13 The current study provides more clinical context on the true incidence of these pathogens over time. Two previous studies identified CRE. 19, 29 In the larger study, CRE was identified in 5%; however the median length of stay was 13 days (IQR 6, 21 days) and only 28% of patients were still admitted at the time of analysis. 29 We found Candida species accounted for 17% of all healthcare-associated infections and Predictors of healthcare-associated infections identified were largely consistent with known risk factors for infections in hospitalized patients. We further identified a significant association between the use of steroids and development of a healthcare-associated infection. Although this association persisted after adjusting for other factors such as need for ICU admission and invasive A c c e p t e d M a n u s c r i p t 15 mechanical ventilation, this finding may reflect use of immunomodulatory agents in patients with more severe COVID-19 or with prolonged hospitalizations. The scope of this study did not allow us to assess steroid dose or duration or the frequency of other opportunistic infections. Tocilizumab, an IL-6 receptor blocker, has been associated with increased risk of serious infections compared to other immunomodulatory agents in patients with rheumatoid arthritis. 37 In a study from Italy evaluating patients with COVID-19 treated with tocilizumab, 13% of patients in the treatment arm developed infections, compared to 4% who received standard of care without tocilizumab. 38 In the United States, superinfections were significantly higher in patients treated with tocilizumab (54%) when compared to controls (26%). 39 We did not find tocilizumab to be independently associated with healthcare-associated infections.

The strengths of this study include evaluation of both community-associated and healthcareassociated secondary infections, extended duration of follow up, inclusion of all hospitalized patients, and evaluation for antimicrobial resistance. However, the study also has several limitations.

Given the rapid influx of patients, ICU units were not clearly delineated and as such ICU admission was likely underreported. Urinary tract infections with pyuria were not evaluated in the context of urinary symptoms. Cultures were usually obtained in the setting of fever or presumed sepsis. While we may be overestimating pneumonias in ventilated patients, positive respiratory cultures were difficult to ignore in this setting and were clinically considered ventilator-associated pneumonias requiring treatment. While it is standard practice to obtain cultures prior to the initiation of antibiotics or before changing antibiotics, the appropriateness of this timing was not evaluated and could result in underreporting of infection rates. While more infections occurred in patients who received steroids, an extensive risk factor analysis in these patients was not completed as it was not the goal of this analysis. Antibiotic use was common, but we did not evaluate antibiotic duration or its relationship to the development of antibiotic resistance. We also could not determine the impact of efforts to limit healthcare worker patient exposure with the frequency of obtaining appropriate cultures. Finally, New York City was an early hot spot in the United States and the rapid influx of A c c e p t e d M a n u s c r i p t 16 patients strained the healthcare system. As such, the generalizability of these results may be limited outside of a pandemic environment and each institution's susceptibility patterns may differ, but they provide insight into the likelihood of bacterial and fungal infections and the need for broadspectrum antibiotic use.

In our quaternary care hospital in New York City, 17% of patients with COVID-19 developed secondary bacterial or fungal infections during the peak of the pandemic. Healthcare-associated infections were not common, but the overwhelming majority were caused by Gram-negative 

All no reported conflicts of interest.

Data not publically available. M a n u s c r i p t 23 A c c e p t e d M a n u s c r i p t 27 M a n u s c r i p t Stenotrophomonas species 0 (0)

Aspergillus species 1 (4) 2 (2) 1 (1) 1 (1)

A c c e p t e d M a n u s c r i p t Fluconazole-resistant n/a n/a n/a n/a n/a M a n u s c r i p t M a n u s c r i p t 31 A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t 36 Figure 2 

Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study

Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing

Bacterial and fungal infections in COVID-19 patients: A matter of concern

Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter Retrospective Cohort Study

Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study

Risk of ruling out severe acute respiratory syndrome by ruling in another diagnosis: variable incidence of atypical bacteria coinfection based on diagnostic assays

The clinical characteristics of secondary infection of lower respiratory in severe acute respiratory syndrome

New York City hospital

Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State

Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in

Co-infection with respiratory pathogens among COVID-2019 cases

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical Characteristics of Covid-19 in New York City

Clinical Features of 69 Cases With Coronavirus Disease

COVID-19 in a designated infectious diseases hospital outside Hubei Province, China